Search academic texts

Information × Registration Number 0307U003147, 0106U011095 , R & D reports Title Two-arm, ramdomized (2:1), open-label phase ІІ/ІІІ study in EpCAM- positive cancer patients with symtomatic malignant ascites using paracentesis plus the tri-functional antibody removabТ (anti EpCAM х anti-CD3) versus paracentesis alone. popup.stage_title Набір пацієнтів для дослідження та проведення циклів лікування, відслідковування виживаності пацієнтів, Статистична обробка результатів дослідження. Head Hotko Evgen Stepanovych, Registration Date 23-01-2007 Organization Uzhgorod National University popup.description2 By results of the work (puncture-free survival, ascite volume collected during therapeutic punctures, abdominal girth and concentration of total protein in ascites) it is demonstrated that the study drug (removab) is effective and safe while symtomatic treatment of malignant ascites in patients with cancer. Besides it is shown that toxic developments can be comparable with the additional therapeutic punctures, but use ov removab is improving patients quality of life.5635 Product Description popup.authors popup.nrat_date 2020-04-02 Close